Psy76 - us payer needs for value demonstration for igg therapies
Payers are seeking more value-based information; emphasis needs to be on demonstrating value, comparative effectiveness, and cost offsets. Payers generally felt the cost differences in route of administration (SC vs. IV) and site may not be as evident as previously reported. Payers are uncertain of total cost of therapy differences, stating that comparisons between IV and SC need to include acquisition costs and administration fees in a transparent comparison of total therapy costs.
Brogan, A., Guptill, JT., Runken, MC., & Hogue, S. (2016). Psy76 - us payer needs for value demonstration for igg therapies. Value in Health, 19(3), A254. DOI: 10.1016/j.jval.2016.03.1015